Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial
Eur Heart J
; 36(46): 3268-3275, 2015.
Artigo
em Inglês
| Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP
| ID: biblio-1062613
Biblioteca responsável:
BR79.1
Localização: BR79.1
ABSTRACT
AIM:
To assess clinical outcomes, efficacy, and safety according to sex during anticoagulation with apixaban compared with warfarin in patients with atrial fibrillation.METHODS ANDRESULTS:
Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) was a randomized, double-blind, placebo-controlled, multicentre trial that included 11 785 (64.7%) men and 6416 (35.3%) women with atrial fibrillation or flutter randomized to receive either warfarin or apixaban. The primary efficacy endpoint was stroke or systemic embolism; secondary efficacy endpoints were death from any cause and cardiovascular death. The primary safety endpoint was major bleeding; secondary safety endpoints were a composite of major bleeding and non-major clinically relevant bleeding. The risk of stroke or systemic embolism was similar in women vs. men [adjusted hazard ratio (adjHR) 0.91; 95% confidence interval (CI) 0.74-1.12; P = 0.38]. However, among patients with history of stroke or transient ischaemic attack, women had a lower risk of recurrent stroke compared with men (adjHR 0.70; 95% CI 0.50-0.97; P = 0.036). Women also had a lower risk of all-cause death (adjHR 0.63; 95% CI 0.55-0.73; P < 0.0001) and cardiovascular death (adjHR 0.62; 95% CI 0.51-0.75; P < 0.0001), and a trend towards less major bleeding (adjHR 0.86; 95% CI 0.74-1.01; P = 0.066) and major or non-major clinically relevant bleeding (adjHR 0.89; 95% CI 0.80-1.00; P = 0.049). The efficacy and safety benefits of apixaban compared with warfarin were consistent regardless of sex.CONCLUSION:
In the ARISTOTLE trial, women had a similar rate of stroke or systemic embolism but a lower risk of mortality and less clinically relevant bleeding than men. The efficacy and safety benefits of apixaban compared with warfarin were consistent in men and women...
Buscar no Google
Coleções:
Bases de dados nacionais
/
Brasil
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
/
ODS3 - Saúde e Bem-Estar
/
ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis
Problema de saúde:
Objetivo 9: Redução de doenças não transmissíveis
/
Meta 3.4: Reduzir as mortes prematuras devido doenças não transmissíveis
/
Doença Cardiovascular
/
Doença Cerebrovascular
Base de dados:
Sec. Est. Saúde SP
/
SESSP-IDPCPROD
Assunto principal:
Fibrilação Atrial
/
Sexo
/
Varfarina
/
Acidente Vascular Cerebral
/
Anticoagulantes
Tipo de estudo:
Ensaio clínico controlado
Idioma:
Inglês
Revista:
Eur Heart J
Ano de publicação:
2015
Tipo de documento:
Artigo
Instituição/País de afiliação:
Boston University Medical Center/US
/
Bristol-Myers Squibb/US
/
Dante Pazzanese Institute of Cardiology/BR
/
Duke University Medical Center/US
/
Hospital Unit West and Aarhus University Hospital/DK
/
INECO Neurociencias Oroño/AR
/
Oslo University Hospital and University of Oslo/NO
/
Oslo University Hospital, and Institute of Clinical Sciences, University of Oslo/NO
/
University of Medicine and Pharmacy Carol Davila/RO
/
Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University/SE